11/4/2026

speaker
Conference Operator
Operator

Good day and thank you for standing by. Welcome to the Biochrist third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Nick Wilder with Biochrist. Nick, go ahead.

speaker
Nick Wilder
BioCryst Investor Relations

Good morning and welcome to Biochrist's third quarter 2026 corporate update and financial results conference call. Participating with me today are President and CEO Charlie Gayer, Chief Financial Officer Babar Ghias, and Chief R&D Officer, Dr. Sandeep Menon. A press release and slide presentation about today's news are available on our investor relations website. Today's call contains forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information, as well as the company's future performance and or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance, or achievements to be materially different from any future results or performance expressed or implied in this presentation. For additional information, including a detailed discussion of these risks, please refer to slide two of the presentation. In addition, today's conference call includes non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures against the most directly comparable GAAP financial measure, Please refer to the earnings press release available on our investor relations website. I'd now like to turn the call over to Charlie.

speaker
Charlie Gayer
President and Chief Executive Officer

Thanks, Nick. The third quarter was significant for Biochrist as we continue to deliver strong execution during a time of strategic evolution. On the HAE front, new patient prescriptions for Orlodeo continued at the same high level that we've seen all year. We again added new prescribers at a rate above the average of the past several years. and the total base of treated patients grew at a healthy rate in the quarter. We were thrilled to launch Orlodeo pellets to kids in August and early signs of performance continue to be promising. Children of all ages across the 2 to 11 range have started on Orlodeo pellets and the mix of kids switching from other prophy and acute only as well as those who were treatment naive has been balanced. This suggests the pediatric market may grow beyond the 500 patients that we have previously described. We are also looking forward to launching the recently approved 150 milligram Orlodeo pellets at the upcoming American College of Allergy, Asthma, and Immunology meeting this month. This new formulation for ages 12 and up provides an option for kids who started on pellets, for adolescents and adults who have difficulty swallowing a capsule, or for anyone who simply prefers the pellet formulation. We are looking forward to generating real world evidence to track the progress and patterns of use for all patients treated with Orlodeo pellets. During the third quarter, we also implemented the transition to CareMed as our sole source pharmacy partner for shipments to patients. We switched to CareMed because the volume of patients on Orlodeo has grown to the point where operational excellence at the pharmacy level can have a significant impact on the growth in treated patients and the shipment in paid product. We are working closely with CareMed to integrate best practices within our Empower Patient Services program and are encouraged by the early signs we are seeing in the partnership. We believe CareMed can scale with us as our portfolio of HEE pro-fee offerings continues to grow. Turning to our pipeline, as we have previously announced, the pivotal trial for NovenaBARC, fully enrolled in June, and we remain on track to announce top line data through 12 months of therapy in the third quarter of next year. Our team is working diligently on the BLA file as well as launch planning for when we add this potentially transformative product to our HAE portfolio. Continuing on the theme of strong execution, we have enrolled part four of our trial of BCX17725 for Netherton syndrome patients and are on track to have early clinical data by the end of this year. There are no treatments approved for this devastating skin condition that we believe includes at least 3,000 patients in the United States alone. Once the data reads out, we will review the data in totality, which includes key efficacy endpoints like IASI, the ichthyosis area severity score, as well as safety and tolerability to inform potential next steps in the program. Finally, we are excited about our strategic shift for building our pipeline through external innovation. We recently announced a scientific advisory board of leading biotech industry experts who will partner with us to deliver on our strategy. These esteemed advisors with a successful track record did not join us just for the honor of being on the board. They joined us because they believe that Biocrist profitability, discipline, and strong execution position the company for success in our rare disease strategy. With that, I'll turn it over to Babar to describe our increasingly strong financial position.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation